CTBP1 and neoplasm: Altogether, these data suggest that Comp.11, with the best results at the dosage of 20 mg/kg, once bound to CtBP1/BARS, inhibits growth of melanoma tumor in xenograft models, indicating its potential effective antitumor activity.